2013-01-03 17:03:49 -

KVISTGAARD, Denmark, January 3, 2013 - Bavarian Nordic (NASDAQ OMX: BAVA)
announced today that Anders Hedegaard, President & CEO will present at the
Biotech Showcase(TM) 2013 Conference in San Francisco, CA on Monday, January
7, 2013 at 11:30 am PST.

The presentation slides will subsequently be available on the company's website:
www.bavarian-nordic.com/investor

Biotech Showcase is an investor and partnering conference devoted to providing
private and public biotechnology and life sciences companies an opportunity to
present to, and meet with, investors and pharmaceutical executives during the
course of one of the industry's largest annual healthcare investor conferences.
The conference is taking place at Parc 55 Wyndham San Francisco - Union Square
Hotel.

Contact
Rolf Sass Sørensen, Vice President Investor Relations & Communications
E-mail: investor@bavarian-nordic.com
Phone: +45 33 26 83 83

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused   biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1667986]